The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes

Cardiovasc Diabetol. 2008 Oct 7:7:29. doi: 10.1186/1475-2840-7-29.

Abstract

Cardiovascular disease is the major cause of morbidity and mortality associated with diabetes. There is increasing evidence that advanced glycation endproducts (AGEs) play a pivotal role in atherosclerosis, in particular in diabetes. AGE accumulation is a measure of cumulative metabolic and oxidative stress, and may so represent the "metabolic memory". Furthermore, increased AGE accumulation is closely related to the development of cardiovascular complications in diabetes. This review article will focus on the clinical relevance of measuring AGE accumulation in diabetic patients by focusing on AGE formation, AGEs as predictors of long-term complications, and interventions against AGEs.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers / blood
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / prevention & control
  • Diabetes Complications / etiology*
  • Diabetes Complications / metabolism
  • Diabetes Complications / prevention & control
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / metabolism*
  • Glycation End Products, Advanced / antagonists & inhibitors
  • Glycation End Products, Advanced / blood*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Microcirculation / metabolism

Substances

  • Biomarkers
  • Glycation End Products, Advanced
  • Hypoglycemic Agents